Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: A cohort analysis of a cluster-randomised trial

British Journal of General Practice

Volumn 64, Issue 621, 2014, Pages

  Black, James A ^a   Sharp, Stephen J ^a   Wareham, Nicholas J ^a   Sandbkæ, Annelli ^b   Rutten, Guy Ehm ^c   Lauritzen, Torsten ^b   Khunti, Kamlesh ^d   Davies, Melanie J ^d   Borch Johnsen, Knut ^b   Griffin, Simon J ^a   Simmons, Rebecca K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cardiovascular diseases; Diabetes mellitus, type 2; Prevention and control; Primary health care; Risk assessment; Risk factors; Treatment heterogeneity

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CREATININE; GLYCOSYLATED HEMOGLOBIN; SERUM ALBUMIN;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SOCIAL STATUS; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; CLUSTER ANALYSIS; DIABETES MELLITUS, TYPE 2; ENGLAND; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLUSTER ANALYSIS; COHORT STUDIES; CREATININE; DENMARK; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NETHERLANDS; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; SURVEYS AND QUESTIONNAIRES; TRIGLYCERIDES;

EID: 84898761227     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp14X677833     Document Type: Article

References (42)

1. Diabetes UK. Early identification of people with and at high risk of type 2 diabetes and interventions for those at high risk. London: Diabetes UK, 2012. https://www.diabetes.org.uk/Documents/Position%20statements/diabetes-uk- position-statement-early-identification-type-2-0513.pdf (accessed 25 Feb 2014).
2. NHS Health Check Programme. Putting prevention first - NHS health check: vascular risk assessment and management best practice guidance. London: NHS, 2009.
3. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837-853.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317(7160): 703-713.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
6. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20(4): 614-620.
7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6): 580-591.
8. Charles M, Simmons RK, Williams KM, et al. Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort. Br J Gen Pract 2012; DOI: 10.3399/ bjgp12X649070.
9. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-167.
10. Lauritzen T, Sandbaek A, Carlsen AH, Borch-Johnsen K. All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. Prim Care Diabetes 2012; 6(3): 193-200.
11. Murphy E, Kinmonth AL. No symptoms, no problem? Patients' understandings of non-insulin dependent diabetes. Fam Pract 1995; 12(2): 184-192.
12. Wienbergen H, Senges J, Gitt AK. Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill? Diabetes Care 2008; 31(suppl 2): S222-S225.
13. Espelt A, Borrell C, Roskam AJ, et al. Socioeconomic inequalities in diabetes mellitus across Europe at the beginning of the 21st century. Diabetologia 2008; 51(11): 1971-1979.
14. Lauritzen T, Griffin S, Borch-Johnsen K, et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24(suppl 3): S6-S11.
15. Echouffo-Tcheugui JB, Simmons RK, Williams KM, et al. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009; 9: 136.
16. Webb DR, Khunti K, Srinivasan B, et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 2010; 11: 16.
17. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009; 59(558): 43-48.
18. National Institute for Health and Clinical Excellence. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: NICE, 2008. http://www.nice.org.uk/nicemedia/pdf/ CG66FullGuideline0509.pdf (accessed 25 Feb 2014).
19. Royal College of General Practitioners in Denmark. Type 2-diabetes in general practice - diagnosis and treatment. Copenhagen: RCGP Denmark, 1999.
20. McIntosh AH, Home P, Brown F, et al. Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose. Sheffield: School of Health and Related Research, University of Sheffield, 2001.
21. Rutten G, Verhoeven S, Heine R, et al. NHG standards for treating type 2 diabetes (first revision). Huisarts Wet 1999; 42: 67-84. [In Danish].
22. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 2012; 19(4): 403-488.
23. Khunti K, Gadsby R, Millett C, et al. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabet Med 2007; 24(12): 1436-1441.
24. Drivsholm T, Snorgaard O. Organisation of treatment and control of type 2 diabetic patients. Ugeskr Laeger 2012; 174(37): 2159-2162. [In Danish].
25. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363(9411): 757-767.
26. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353(9153): 617-622.
27. Coleman R, Stevens R, Holman R. Updated UKPDS risk engine that estimates primary and secondary cardiovascular disease risk in people with recently-diagnosed or established type 2 diabetes. Diabetes 2012; 61(suppl 1): A264.
28. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095-1108.
29. Tu Y-K, Gilthorpe MS. Revisiting the relation between change and initial value: a review and evaluation. Stat Med 2007; 26(2): 443-457.
30. Chamnan P, Simmons RK, Sharp SJ, et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009; 52(10): 2001-2014.
31. van Dieren S, Peelen LM, Nothlings U, et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 2011; 54(2): 264-270.
32. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model (UKPDS no. 68). Diabetologia 2004; 47(10): 1747-1559.
33. Ahmad Kiadaliri A, Clarke PM, Gerdtham UG, et al. Predicting changes in cardiovascular risk factors in type 2 diabetes in the post-UKPDS era: longitudinal analysis of the Swedish National Diabetes Register. J Diabetes Res 2013; 2013: 241347.
34. Davis TME, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55). Diabetes Care 2001; 24(7): 1167-1174.
35. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006; 55(suppl 1(0)): S2-S5.
36. Davies M, Heller S, Skinner T, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008; 336(7642): 491-495.
37. Khunti K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ 2012; 344: e2333.
38. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013; 36(suppl 1): S11-S66.
39. Winkley K, Thomas SM, Sivaprasad S, et al. The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D). Diabetologia 2013; 56(6): 1272-1281.
40. Chaturvedi N, Jarrett J, Shipley MJ, Fuller JH. Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall study and the WHO multinational study of vascular disease in diabetes. BMJ 1998; 316(7125): 100-105.
41. Zeh P, Sandhu HK, Cannaby AM, Sturt JA. The impact of culturally competent diabetes care interventions for improving diabetes-related outcomes in ethnic minority groups: a systematic review. Diabet Med 2012; 29(10): 1237-1352.
42. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl 5): v1-v52.